{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:14:35Z","timestamp":1753892075115,"version":"3.41.2"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008678","name":"Universit\u00e4t Leipzig","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008678","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>The larynx organ preservation (LOP) trial DeLOS-II enrolled <jats:italic>n<\/jats:italic> = 173 patients with advanced laryngeal\/hypopharyngeal squamous cell carcinoma (LHSCC) amenable (only curatively resectable) through total laryngectomy (TL) to receive induction chemotherapy (IC) with TPF [docetaxel (T), cisplatin (P), and 5-fluorouracil (F)] (arm A, 85 patients) or additional cetuximab (E) weekly (arm B, 88 patients). Responders with endoscopic estimated tumor surface shrinkage (ETSS) \u226530% after 1 cycle IC (IC-1) received a further two cycles of IC followed by radiotherapy (RT), whereas TL was recommended for non-responders. Arm B failed to show superior 24-month laryngectomy-free survival (LFS) and overall survival (OS), the protocol-specified primary and secondary endpoints. Ten years after the last per-protocol visit, we are interested in the long-term outcome of our clinic\u2019s DeLOS-II patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Our cohort of 52 DeLOS-II patients accrued between 2007 and 2012 included 27 and 25 patients randomized to arms A and B, respectively. F was omitted because of severe toxicity with amendment 2 of the DeLOS-II protocol, leading to 21 and 31 patients receiving TPF and TP IC backbone, respectively. Follow-up data were collected using electronic health records and information from the German Centre for Cancer Registry Data to evaluate long-term LFS and OS in treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>According to ETSS \u2265 30%, 42 patients (80.8%; 21 and 21 corresponding to 77.8% and 84.0% in arms A and B, respectively) were responders to IC-1 and underwent the LOP attempt. Recommending early TL to non-responders (ETSS &amp;lt; 30%), eight patients (five and three in A and B, respectively) underwent early TL. At 125 months, 22 (eight and 14) patients were alive: 17 (six and 11) with a functioning larynx and five (two and three) without a larynx. Arm B had superior OS (<jats:italic>p<\/jats:italic> = 0.023). Disease-specific survival (DSS) and tumor-specific survival were not different, whereas non-cancer-related survival (NCRS) was impaired in arm A (<jats:italic>p<\/jats:italic> = 0.018). Receiving TP or TPF IC did not significantly influence survival. Pairwise comparing OS of patients receiving TP, TPF, TPE, and TPFE revealed a benefit from cetuximab in TPE <jats:italic>vs<\/jats:italic>. TP (<jats:italic>p<\/jats:italic> = 0.020).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>While the per-protocol DeLOS-II results earlier reported comparable 24-month LFS and OS in arms A and B, our subcohort\u2019s long-term follow-up data demonstrate a superior 125-month outcome in arm B.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1506840","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T07:01:46Z","timestamp":1735023706000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Superior 125-month outcome through cetuximab in the larynx organ preservation trial DeLOS-II: a single study center\u2019s experience"],"prefix":"10.3389","volume":"14","author":[{"given":"Gunnar","family":"Wichmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Wald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veit","family":"Zebralla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthaeus","family":"Stoehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Pirlich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Wiegand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer","volume":"349","author":"Forastiere","year":"2003","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.6097","article-title":"Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer","volume":"31","author":"Forastiere","year":"2013","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199106133242402","article-title":"Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer","volume":"324","author":"Wolf","year":"1991","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1093\/jnci\/djp007","article-title":"Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation","volume":"101","author":"Pointreau","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-008-0846-y","article-title":"Induction chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx organ preservation in advanced laryngeal and hypopharyngeal cancer offers moderate late toxicity outcome (DeLOS-I-trial)","volume":"266","author":"Dietz","year":"2009","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.4559","article-title":"American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer","volume":"24","author":"Pfister","year":"2006","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12031131","article-title":"Docetaxel-cisplatin-fluorouracil induction chemotherapy for larynx preservation in patients with locally advanced hypopharyngeal cancer: predictive factors of oncologic and functional outcomes","volume":"12","author":"Mattei","year":"2023","journal-title":"J Clin Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/hed.21081","article-title":"Larynx preservation clinical trial design: Key issues and recommendations\u2013a consensus panel summary","volume":"31","author":"Lefebvre","year":"2009","journal-title":"Head Neck"},{"key":"B11","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ijrobp.2015.03.004","article-title":"Total laryngectomy versus larynx preservation for T4a larynx cancer: patterns of care and survival outcomes","volume":"92","author":"Grover","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29241","article-title":"Long-term outcomes after surgical or nonsurgical initial therapy for patients with T4 squamous cell carcinoma of the larynx: A 3-decade survey","volume":"121","author":"Rosenthal","year":"2015","journal-title":"Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy332","article-title":"Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal\/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II","volume":"29","author":"Dietz","year":"2018","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.11.013","article-title":"Induction chemotherapy followed by radiotherapy for larynx preservation in advanced laryngeal and hypopharyngeal cancer: Outcome prediction after one cycle induction chemotherapy by a score based on clinical evaluation, computed tomography-based volumetry and (18)F-FDG-PET\/CT","volume":"72","author":"Wichmann","year":"2017","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1394691","article-title":"Improved survival of locoregional-advanced larynx and hypopharynx cancer patients treated according to the DeLOS-II protocol","volume":"14","author":"Wichmann","year":"2024","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"B18","article-title":"Evaluation of survival data and two new rank order statistics arising in its consideration","volume":"50","author":"Mantel","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life-tables. Royal statistical society","volume":"34","author":"Cox","year":"1972","journal-title":"J Ser B: Methodological"},{"key":"B20","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M14-0698","article-title":"Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration","volume":"162","author":"Moons","year":"2015","journal-title":"Ann Intern Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00625","article-title":"Laryngeal preservation approaches: considerations for new selection criteria based on the deLOS-II trial","volume":"9","author":"Dietz","year":"2019","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8001","article-title":"Different view on larynx preservation evidence-based treatment recommendations","volume":"36","author":"Licitra","year":"2018","journal-title":"J Clin Oncol"},{"key":"B23","article-title":"Salvage surgery in post-chemoradiation laryngeal and hypopharyngeal carcinoma: outcome and review","volume":"35","author":"van der Putten","year":"2015","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1055\/a-1058-0171","article-title":"Automatic calculation and visualization of comorbidity scores for decision-making in tumor boards","volume":"99","author":"Wald","year":"2020","journal-title":"Laryngorhinootologie"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.795277","article-title":"Cytokine profiles of head and neck squamous cell carcinoma undergoing dual immunotherapy with cetuximab and pembrolizumab identify interferon gamma-induced protein 10 as novel biomarker","volume":"12","author":"Berszin","year":"2022","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0802656","article-title":"Platinum-based chemotherapy plus cetuximab in head and neck cancer","volume":"359","author":"Vermorken","year":"2008","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00383","article-title":"Cetuximab-containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma","volume":"9","author":"Taberna","year":"2019","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.715297","article-title":"Choosing the right treatment option for the right R\/M HNSCC patient: should we adhere to PFE for first-line therapy","volume":"11","author":"L\u00fcbbers","year":"2021","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30755-5","article-title":"Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial","volume":"22","author":"Guigay","year":"2021","journal-title":"Lancet Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.3988","article-title":"Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study","volume":"31","author":"Lefebvre","year":"2013","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv368","article-title":"Long-term results of a multicenter randomized phase III trial of induction chemotherapy with cisplatin, 5-fluorouracil, \u00b1 Docetaxel for larynx preservation","volume":"108","author":"Janoray","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.24.18_suppl.5516","article-title":"A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN). Final analysis of EORTC 24971","volume":"24","author":"Remenar","year":"2006","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-00710-9","article-title":"Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer","volume":"34","author":"Emancipator","year":"2021","journal-title":"Mod Pathol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: A multicenter, phase II trial","volume":"26","author":"Uppaluri","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1433238","article-title":"The european larynx organ preservation study MK-3475-C44","volume":"14","author":"Wichmann","year":"2024","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.549915","article-title":"Obtaining patient-reported outcomes electronically with \"OncoFunction\" in head and neck cancer patients during aftercare","volume":"10","author":"Zebralla","year":"2020","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/biology10020144","article-title":"Course of self-reported dysphagia, voice impairment and pain in head and neck cancer survivors","volume":"10","author":"Zebralla","year":"2021","journal-title":"Biol (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2017.04.017","article-title":"HLA traits linked to development of head and neck squamous cell carcinoma affect the progression-free survival of patients","volume":"69","author":"Wichmann","year":"2017","journal-title":"Oral Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00168","article-title":"Development of a human leukocyte antigen score to predict progression-free survival in head and neck squamous cell carcinoma patients","volume":"8","author":"Wichmann","year":"2018","journal-title":"Front Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00191","article-title":"Perspectives of induction with chemo and\/or immune check point inhibition in head and neck organ preservation treatment","volume":"9","author":"Wiegand","year":"2019","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1433333","article-title":"Is precision medicine the solution to improve organ preservation in laryngeal\/hypopharyngeal cancer? A position paper by the Preserve Research Group","volume":"14","author":"Mattavelli","year":"2024","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1506840\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T07:01:48Z","timestamp":1735023708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1506840\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":43,"alternative-id":["10.3389\/fonc.2024.1506840"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1506840","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"article-number":"1506840"}}